Do we use the right criteria for determining the clinical significance of incidental prostate cancer at radical cystoprostatectomy?

Scandinavian Journal of Urology

Volumn 47, Issue 5, 2013, Pages 358-362

  Gakis, Georgios ^a   Stenzl, Arnulf ^a   Renninger, Markus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Incidental; Prostate cancer; Prostate stem cell antigen; Radical cystoprostatectomy; Rs2294008; Rs3736001; Single nucleotide polymorphism

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN;

BLADDER CANCER; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GLEASON SCORE; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; INCIDENTAL FINDING; INVASIVE BLADDER CANCER; LYMPH NODE METASTASIS; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL CYSTOPROSTATECTOMY; RECURRENCE RISK; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSURETHRAL RESECTION;

AGE FACTORS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; COMORBIDITY; GPI-LINKED PROTEINS; HUMANS; INCIDENTAL FINDINGS; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84885393731     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/00365599.2012.723045     Document Type: Review

References (30)

1. Damiano R, Di Lorenzo G, Cantiello F, De Sio M, Perdonà S, D'Armiento M, et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 2007;52:648-57.
2. Kefer JC, Cherullo EE, Jones JS, Gong MC, Campbell SC. Prostate-sparing cystectomy: has Pandora's box been opened? Expert Rev Anticancer Ther 2007;7:1003-14.
3. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 2001;19:666-75.
4. Sruogis A, Ulys A, Smailyte G, Kardelis Z, Kulboka A, Anglickiene G, et al. Incidentally found prostate cancer and influence on overall survival after radical cystoprosta-tectomy. Prostate Cancer 2012;690210. [Epub Jun 3, 2012]
5. Gakis G, Schilling D, Bedke J, Sievert KD, Stenzl A. Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int 2010;105:468-71.
6. Moutzouris G, Barbatis C, Plastiras D, Mertziotis N, Katsifotis C, Presvelos V, et al. Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol 1999;33:27-30.
7. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, et al. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morpho-metric comparison with clinically detected cancer in totally embedded specimens. Hum Pathol 2005;36:646-54.
8. Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T. Characteristics of incidental prostatic adeno-carcinoma in contemporary radical cystoprostatectomy specimens. BJU Int 2007;99:554-8.
9. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
10. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271: 376-84.
11. Wolters T, Montironi R, Mazzucchelli R, Scarpelli M, Roobol MJ, van den Bergh RC, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121-5.
12. Joung JY, Yang SO, Seo HK, Kim TS, Han KS, Chung J, et al. Incidental prostate cancer detected by cysto-prostatectomy in Korean men. Urology 2009;73:153-7.
13. Bryniarski P, Fryczkowski M, Pawlaczek P, Pliszek K, Prokopowicz G, Kaletka Z, et al. Prognostic value of radical cystoprostatectomy in men with bladder cancer infiltrating prostate versus coexisting prostate cancer: a research study. BMC Urol 2010;10:16.
14. Delongchamps NB, Mao K, Theng H, Zerbib M, Debré B, Peyromaure M, et al. Outcome of patients with fortuitous prostate cancer after radical cystoprostatectomy for bladder cancer. Eur Urol 2005;48:946-50.
15. Pritchett TR, Moreno J, Warner NE, Lieskovsky G, Nichols PW, Cook BA, et al. Unsuspected prostatic adeno-carcinoma in patients who have undergone radical cystopros-tatectomy for transitional cell carcinoma of the bladder. J Urol 1988;139:1214-16.
16. Abbas F, Hochberg D, Civantos F, Soloway M. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol 1996;30: 322-6.
17. Abdelhady M, Abusamra A, Pautler SE, Chin JL, Izawa JI. Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int 2007;99: 326-9.
18. Kouriefs C, Fazili T, Masood S, Naseem MS, Mufti GR. Incidentally detected prostate cancer in cystoprostatectomy specimens. Urol Int 2005;75:213-16.
19. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
20. Bulbul MA, Wazzan W, Farhat W, Kaouk J, Hemady K, Shamseddine AI. Feasibility of radiation and chemotherapy following cystectomy and orthotopic neobladder for invasive bladder cancer. Can J Urol 1998;5:469-71.
21. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735-40.
22. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 2002;16:2323-37.
23. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-96.
24. Bahrenberg G, Brauers A, Joost HG, Jakse G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun 2000;275:783-8.
25. Zhigang Z, Wenlu S. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005;65:299-305.
26. Zhigang Z, Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. Int J Cancer 2008;122:864-70.
27. Zhao Z, Ma W, Zeng G, Qi D. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. J Surg Oncol 2011;104:672-8.
28. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009;41:991-5
29. Study Group of Millennium Genome Project for Cancer. Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40:730-40.
30. Joung JY, Lee YS, Park S, Yoon H, Lee SJ, Park WS, et al. Haplotype analysis of prostate stem cell antigen and association with prostate cancer risk. J Urol 2011;185: 2112-18.